Abstract:Purpose of review A growing number of gene therapies are getting FDA-approved for pediatric rare disorders to treat once incurable diseases. Opportunities for preventing lifetime illness and improving quality of life for these patients is now becoming a reality. Challenges exist in navigating the complexities of determining which patients will benefit from these new gene therapies and how to effectively deliver them as a standard of care. Recent findings Gene therapies have been approved for pediatric hematological, neuromuscular, cancer, and other disorders that have improved the quality of life for rare disease patients. FDA approval of these drugs has been on a case-by-case basis leading towards gaps in drug approval, physician and patient knowledge of new gene therapies, and ultimate delivery of these drugs. Identifying patients that would benefit from these drugs and other coordination of care issues have arisen with each unique gene therapy product. These gene therapies have unique requirements and patient indications that require a knowledgeable group of physicians and hospital administrators to incorporate their use as a standard of care. With more gene therapies on the near horizon for FDA approval, multidisciplinary teams may improve patient access to these drugs by streamlining approaches towards adapting gene therapies into clinical use. Summary The rapid increase in the number of FDA-approved gene therapies has not only created a number of challenges but also opportunities to improve the lives of pediatric patients with rare disorders. The adaptability of physicians, hospitals, and governmental regulatory boards is essential for delivering these new gene therapies safely and efficiently to these rare disease patients. Challenges still remain as to future requirements for additional gene therapy dosing and how to best manage financial burdens placed on the patient and providing institution.

Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations

Gene Therapy for Monogenic Disorders: Challenges, Strategies, and Perspectives

Gene therapy for polygenic or complex diseases

Next-Generation Therapeutics for Rare Genetic Disorders

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

mRNA therapies: Pioneering a new era in rare genetic disease treatment

The special considerations of gene therapy for mitochondrial diseases

Improving access to gene therapy for rare diseases

Pharmacogenomics of Rare and Monogenic Disorders

State of Gene Therapy for Monogenic Cardiovascular Diseases

Gene Therapy: Regulations, Ethics and Its Practicalities in Liver Disease

Research Progress in Mitochondrial Gene Editing Technology.

Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation

Genetic Treatment Approaches in Rare Pediatric Diseases

Gene therapy for mitochondrial disorders

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Gene therapy for cardiac diseases: methods, challenges, and future directions

Applications and Developments of Gene Therapy Drug Delivery Systems for Genetic Diseases

Riding the gene therapy wave: challenges and opportunities for rare disease patients and clinicians